Structure-based discovery of dipeptidyl peptidase IV inhibitors

全世界约有1.51亿人患有糖尿病，预计到2010年将增加到2.21亿人。迄今为止，没有一种治疗糖尿病并发症的方法被广泛接受。二肽基肽酶IV作为治疗2型糖尿病的靶点已经显示出有希望的结果。二肽基肽酶IV与抑制剂复合物的结构研究将进行，以阐明酶-抑制剂相互作用的细节。该结果将用于确定二肽基肽酶IV抑制剂的效价和选择性的分子基础，并可能导致发现治疗糖尿病患者的药物。

Diabetes afflicts approximately 151 million people worldwide, with an estimated increase to 221 million by 2010. To date, no therapy for the treatment of diabetes complications is widely accepted. The enzyme dipeptidyl peptidase IV has shown promising results as a target for the treatment of type 2 diabetes. Structural studies of dipeptidyl peptidase IV in complex with inhibitor will be conducted to elucidate the details of the enzyme-inhibitor interaction. The results will be used to identify the molecular basis of potency and selectivity of dipeptidyl peptidase IV inhibitors and may lead to the discovery of pharmaceutical agents for the treatment of diabetes sufferers.